Welcome to our dedicated page for ImageneBio news (Ticker: IMA), a resource for investors and traders seeking the latest updates and insights on ImageneBio stock.
ImageneBio, Inc. develops therapeutics for immunological, autoimmune and inflammatory diseases, led by IMG-007, a non-T cell-depleting, ADCC-silenced anti-OX40 receptor antagonist with an extended half-life. News about IMA centers on clinical program updates for atopic dermatitis and alopecia areata, preclinical data presentations, research and development spending, and financial results.
The company’s updates also cover financing activity, including private placements and pre-funded warrants, as well as governance and compensation matters such as inducement grants and management appointments. ImageneBio was formed and funded through a completed reverse merger with Ikena Oncology and a concurrent private placement in 2025.
ImageneBio, Inc. (NASDAQ: IMA) has completed its merger with Ikena Oncology, combining their operations with a concurrent $75 million private placement from investors including Deep Track Capital, Foresite Capital, and RTW Investments. The merged entity will begin trading on July 28, 2025, under the ticker symbol "IMA".
The transaction includes a 1-for-12 reverse stock split of Ikena's common stock. Post-merger ownership structure comprises 43.1% Inmagene legacy holders, 35.3% Ikena legacy holders, and 21.6% new investors, with approximately 11.6 million shares outstanding. The company, led by CEO Dr. Kristin Yarema, will continue developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, with Phase 2b topline data in atopic dermatitis expected in Q4 2026.